Modified Release Oral Formulation

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Cytokinetics
CytokineticsSOUTH SAN FRANCISCO, CA
1 program
1
Omecamtiv Mecarbil Matrix F1 FormulationPhase 21 trial
Active Trials
NCT01786512Completed544Est. Aug 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CytokineticsOmecamtiv Mecarbil Matrix F1 Formulation

Clinical Trials (1)

Total enrollment: 544 patients across 1 trials

NCT01786512CytokineticsOmecamtiv Mecarbil Matrix F1 Formulation

COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure

Start: Feb 2013Est. completion: Aug 2015544 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space